期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

绝经前后卵巢癌患者细胞因子、免疫状况和生存分析

Cytokines,Immunological Status and Survival Analysis in Pre-and Postmenopausal Patients with Epithelial Ovarian Cancer
原文传递
导出
摘要 [目的]探讨绝经前后卵巢癌患者临床病理因素、细胞因子、CA125和机体免疫状况的差异,以及这些因素对绝经前后卵巢癌患者生存的影响。[方法]收集了2003~2005年浙江省肿瘤医院55例绝经前卵巢癌和55例绝经后卵巢癌患者。回顾性分析了这两组患者临床病理因素、血清细胞因子、外周血淋巴细胞亚群以及血清CA125的差异。[结果]绝经前后卵巢癌患者细胞因子表达无显著性差异,但绝经后卵巢癌患者肿瘤低分化的比例高于绝经前卵巢癌患者(76.4%vs58.2%,P<0.05),而且绝经后卵巢癌患者CD4+细胞比例异常显著高于绝经前患者(60.0%vs36.4%,P<0.05)。绝经后卵巢癌患者3年和5年生存率均分别低于绝经前卵巢癌患者(47.3%vs63.6%;24.3%vs53.3%),绝经后卵巢癌患者中位总生存时间明显低于绝经前卵巢癌患者(34个月vs64个月,P<0.01)。血清CA125高的绝经前卵巢癌患者死亡风险比CA125正常的患者高(HR=2.67;P=0.053);CD3+细胞比例异常的绝经前卵巢癌患者预后比CD3+细胞比例正常患者差(HR=2.94;P=0.016);接受了>6个周期化疗的绝经后卵巢癌患者比... [Purpose]To investigate the difference of clinical-pathological factors,cytokines,CA125 and immunological status in pre-and postmenopausal epithelial ovarian cancer,and the impact of these variates on survival.[Methods]This study included 55 premenopausal and 55 postmenopausal patients with epithelial ovarian cancer in Zhejiang Cancer Hospital from 2003 to 2005.The difference of clinical-pathological factors,serum cytokines,lymphocyte subset and serum CA125 between pre-and postmenopausal epithelial ovarian ...
作者 苏丹 许沈华 朱欣 朱赤红 谢锦波
机构地区 浙江省肿瘤研究所浙江省肿瘤医院
出处 《肿瘤学杂志》 CAS 2009年第12期1124-1128,共5页 Journal of Chinese Oncology
基金 卫生部科学研究基金-浙江省医药卫生重大科技计划基金资助项目(WKJ2006-2-009)
关键词 卵巢肿瘤 预后 生存时间 绝经前 绝经后 ovarian neoplasms prognosis survival premenopause postmenopause
分类号 R737.31 [医药卫生—肿瘤]
  • 相关文献

参考文献10

  • 1Chan JK,,Urban R,Cheung MK,et al.Ovarian cancer in younger vs older women:a population-based analysis[].British Journal of Cancer.2006
  • 2O’Malley CD,Cress RD,Campleman SL,et al.Survival of Californian women with epithelial ovarian cancer,1994~1996:a population-based study[].Gynecologic Oncology.2003
  • 3Jemal A,Siegel R,Ward E,et al.Cancer statistics, 2008[].CA a Cancer Journal for Clinicians.2008
  • 4Aravantinos,G,Fountzilas,G,Kosmidis,P.Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study[].Annals of Oncology.2005
  • 5Plaxe,SC,Braly,PS,Freddo,JL,McClay,E,Kirmani,S,Howell,SB.Profiles of women age 30–39 and age less than 30 with epithelial ovarian cancer[].Obstetrics and Gynecology.1993
  • 6Barnholtz-Sloan JS,Schwartz AG,Qureshi F,et al.Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades[].American Journal of Obstetrics and Gynecology.2003
  • 7John K.Chan,MD,,Vera Loizzi,MD,,Yvonne G.Lin,MD,et al.Stage III and IV Invasive EPithelial Ovarian Carcinoma in Younge Versus Older women:What Prognostic Factors Are ImPortant? The American College of Obstetricians and Gynecologists.[].Obstetrics and Gynecology.2003
  • 8Rodriguez M,Nguyen HN,Averette HE,et al.National survey of ovarian carcinoma Ⅻ.Epithelial ovarian malignancies in women less than or equal to 25 years of age[].Cancer.1994
  • 9Leveque L,Deknuydt F,Bioley G, et al.Interleukin 2-mediated conversion of ovarian cancer-associated CD4+ regulatory T cells into proinflammatory interleukin 17-producing helper T cells[].Journal of Immunotherapy.2009
  • 10T. Giglio M. A. Imro G. Filaci M. Scudeletti F. Puppo L. De Cecco F. Indiveri and S. Costantini.Immune cell circulating subsets are affected by gonadal function[].Life Sciences.
肿瘤学杂志
2009年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部